Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.
SWOG S2210 is a phase 2 trial testing the use of biomarker-guided neoadjuvant carboplatin, a safe and accessible chemotherapy agent, for patients with localized high-risk prostate cancer and inherited
APA
Cheng HH, Callis S, et al. (2026). Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.. European urology focus, 12(1), 16-18. https://doi.org/10.1016/j.euf.2025.11.011
MLA
Cheng HH, et al.. "Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.." European urology focus, vol. 12, no. 1, 2026, pp. 16-18.
PMID
41354605
Abstract
SWOG S2210 is a phase 2 trial testing the use of biomarker-guided neoadjuvant carboplatin, a safe and accessible chemotherapy agent, for patients with localized high-risk prostate cancer and inherited BRCA1/2 mutations. The endpoints are pathologic complete response rates and survival outcomes.
MeSH Terms
Humans; Male; Carboplatin; Prostatic Neoplasms; Neoadjuvant Therapy; Germ-Line Mutation; Clinical Trials, Phase II as Topic; BRCA2 Protein; Antineoplastic Agents; BRCA1 Protein; Genes, BRCA2
같은 제1저자의 인용 많은 논문 (3)
- NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
- BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.
- Coverage of wounds in the distal lower leg by advancement of an enlarged medial gastrocnemius skin flap.